Edison Investment Research is terminating coverage on Xbrane Biopharma, Is Private Equity, Max 21, Elk Petroleum and Centrale del Latte d'Italia. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via <a href="edisongroup.com">our website</a>.
